Lv1
24 积分 2025-01-10 加入
The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders
3个月前
已完结
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
3个月前
已完结
Glutamic-pyruvic transaminase 1 deficiency–mediated metabolic reprogramming facilitates colorectal adenoma-carcinoma progression
4个月前
已完结
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
5个月前
已完结
Linker Design for the Antibody Drug Conjugates: A Comprehensive Review
5个月前
已完结
Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate
5个月前
已完结
British Association for Sexual Health and HIV National Guideline on the Management of Scabies in adults 2025
5个月前
已完结
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834
5个月前
已完结
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
5个月前
已完结
Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations
5个月前
已完结
皖公网安备34019202002308
